- Home
- IONS vs CDE Comparison
IONS vs CDE Comparison
Compare IONS & CDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CDE
- Stock Information
- Founded
- IONS 1989
- CDE 1928
- Country
- IONS United States
- CDE United States
- Employees
- IONS N/A
- CDE N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CDE Precious Metals
- Sector
- IONS Health Care
- CDE Basic Materials
- Exchange
- IONS Nasdaq
- CDE Nasdaq
- Market Cap
- IONS 5.9B
- CDE 4.9B
- IPO Year
- IONS 1991
- CDE N/A
- Fundamental
- Price
- IONS $37.41
- CDE $8.82
- Analyst Decision
- IONS Buy
- CDE Strong Buy
- Analyst Count
- IONS 18
- CDE 4
- Target Price
- IONS $57.59
- CDE $8.00
- AVG Volume (30 Days)
- IONS 1.5M
- CDE 15.4M
- Earning Date
- IONS 07-31-2025
- CDE 08-06-2025
- Dividend Yield
- IONS N/A
- CDE N/A
- EPS Growth
- IONS N/A
- CDE N/A
- EPS
- IONS N/A
- CDE 0.28
- Revenue
- IONS $717,253,000.00
- CDE $1,201,008,000.00
- Revenue This Year
- IONS $7.98
- CDE $66.13
- Revenue Next Year
- IONS $16.09
- CDE $2.80
- P/E Ratio
- IONS N/A
- CDE $31.10
- Revenue Growth
- IONS N/A
- CDE 41.80
- 52 Week Low
- IONS $23.95
- CDE $4.57
- 52 Week High
- IONS $52.34
- CDE $9.69
- Technical
- Relative Strength Index (RSI)
- IONS 68.61
- CDE 62.68
- Support Level
- IONS $34.78
- CDE $9.03
- Resistance Level
- IONS $37.54
- CDE $9.30
- Average True Range (ATR)
- IONS 1.06
- CDE 0.31
- MACD
- IONS 0.07
- CDE -0.09
- Stochastic Oscillator
- IONS 95.44
- CDE 50.00
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.